详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population

2| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China. [2]Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, China. [3]Institute of Neuroscience and Physiology, University of Gothenburg, Molndal, Sweden. [4]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden. [5]School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China. [6]Division of Life Science, The Hong Kong University of Science and Technology, Hong Kong Special Administrative Region, China. [7]Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [8]Westlake and Shenzhen Medical Academy of Research and Translation PhD Program, Westlake University, Hangzhou, China. [9]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. [10]Department of Neurology, Peking University Shenzhen Hospital, Shenzhen, China. [11]Neurology Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China. [12]Department of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen, China. [13]School of Life Science and Technology, Harbin Institute of Technology, Harbin, China. [14]School of Biomedical Engineering, Hainan University, Haikou, China. [15]School of Pharmaceutical Sciences, Shenzhen Campus of Sun Yat-sen University, Shenzhen, China. [16]Department of Neurology, Shenzhen Guangming District People’s Hospital, Shenzhen, China. [17]Department of Medical Imaging, Shenzhen Guangming District People’s Hospital, Shenzhen, China. [18]Department of Nuclear Medicine, The First Affiliated Hospital, Guangzhou Medical University,Guangzhou, China. [19]Department of Nuclear Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China. [20]Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China. [21]Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China. [22]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China. [23]National Clinical Research Center for Geriatric Diseases, Beijing, China. [24]The Central Hospital of Karamay, Xinjiang, China. [25]Paris Brain Institute, ICM, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. [26]Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, China. [27]Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China. [28]Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Peking University, Shenzhen, China.

出处：

DOI：

摘要：

Over 20% of patients with Alzheimer's disease (AD) worlwide are Chinese, although the efficacy of existing blood-based measures of AD biomarkers is largely unknown in Asian cohorts. Here we explored how plasma tau biomarkers correlated with cross-sectional and longitudinal AD-related outcomes and their diagnostic performance in 1,085 participants from three independent studies, including two Chinese cohorts, Greater-Bay-Area Healthy Aging Brain Study (n = 425) and Huashan (n = 297), and the North American Alzheimer's Disease Neuroimaging Initiative cohort (n = 363). Plasma p-tau217 performed best in classifying A beta-positron emission tomography (PET) and tau-PET positivity throughout the AD continuum and correlated with all AD-related outcomes. A two-cutoff approach suggested that participants with intermediate plasma p-tau217 levels experienced rapid accumulation of A beta-PET and entorhinal tau-PET, as well as accelerated hypometabolism and cognitive decline. Increased plasma p-tau217 was also associated with rapid longitudinal changes in A beta-PET, tau-PET and neurodegeneration. These results suggest that plasma p-tau217 is superior in detecting multiple aspects of AD-related pathological changes and tracking disease progression.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 1 区

医学

小类 | 1 区细胞生物学 1 区老年医学 1 区神经科学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区细胞生物学 1 区老年医学 1 区神经科学

JCR分区：

出版当年[2023]版：

Q1 CELL BIOLOGY Q1 GERIATRICS & GERONTOLOGY Q1 NEUROSCIENCES

最新[2024]版：

Q1 CELL BIOLOGY Q1 GERIATRICS & GERONTOLOGY Q1 NEUROSCIENCES

影响因子： 19.4 最新[2024版] 21.9 最新五年平均 17 出版当年[2023版] 17 出版当年五年平均 16.6 出版前一年[2022版] 19.4 出版后一年[2024版]

第一作者：

第一作者机构： [1]Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.

共同第一作者：

通讯作者：

通讯机构： [1]Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China. [3]Institute of Neuroscience and Physiology, University of Gothenburg, Molndal, Sweden. [4]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden. [25]Paris Brain Institute, ICM, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. [26]Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, China. [27]Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China. [28]Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Peking University, Shenzhen, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：